Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
Recruiting now · Phase 3
Conditions studied: First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
In brief
This is a randomized, controlled, open-label, multicenter, phase Ш clinical study designed to compare the efficacy and safety of KN026 in combination with HB1801 to trastuzumab in combination with pertuzumab and docetaxel in the first-line treatment of subjects with HER2-positive recurrent or metastatic breast cancer. The statistical assumption for this study is superiority. The primary study endpoint was PFS as assessed by Blinded Independ Review Committee (BIRC).
Key facts
- Study ID
- NCT05838066
- Run by
- Shanghai JMT-Bio Inc.
- People needed
- 880
- Starts
- 2023-07-23
- Expected to finish
- 2027-12-31
- Last updated by the study team
- 2025-05-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Clinical Trials Information Group — Beijing, chaoyang, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.